467 patents currently held
90 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
3 more records may belong here and await a decision; they are not counted.
The next term ends in Jan 2027. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
47
Ending by 2030
Jan 2027
Next term end
344
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Jul 2038 · High confidence
Also notable
Ends May 2027 · Medium confidence
Also notable
Ends Sep 2030 · High confidence
Cardiac Valve Leaflet Enhancer Devices and Systems
US 11,571,305
Cited by 35 later US patents, top 5% of utility patents granted in 2023 in our data. Protection runs to 2038.
Methods and Devices for Drug Delivery to Ocular Tissue Using Microneedle
US 10,905,586
Cited by 18 later US patents, top 10% of utility patents granted in 2021 in our data. Protection runs to 2027. A terminal disclaimer caps this term to an earlier patent's.
Subunit Selective NMDA Receptor Potentiators For The Treatment Of Neurological Conditions
US 8,822,462
Cited by 45 later US patents, top 25% of utility patents granted in 2014 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2030.
Formerly held, still cited
Notable
Ends Sep 2029 · High confidence
The most cited patent in this portfolio, cited by 314 later US patents, top 1% of utility patents granted in 2013 in our data. Protection runs to 2029.
now held by Dana-Farber Cancer Institute, Inc.
Also notable
Ends Feb 2029 · High confidence
Cited by 258 later US patents, top 5% of utility patents granted in 2011 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2029.
now held by Georgia Tech Research Corporation
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 3 fees due Nov 16 to 19, 2026 · next Nov 16
- 7 fees due Dec 6 to 23, 2026 · next Dec 6
- 6 fees due Jan 2 to 28, 2027 · next Jan 2
- 16 fees due Feb 1 to 28, 2027 · next Feb 1
- 6 fees due Mar 5 to 24, 2027 · next Mar 5
- 8 fees due Apr 3 to 30, 2027 · next Apr 3
- 8 fees due May 5 to 28, 2027 · next May 5
- 9 fees due Jun 8 to 26, 2027 · next Jun 8
- 16 fees due Jul 2 to 30, 2027 · next Jul 2
- 5 fees due Aug 11 to 27, 2027 · next Aug 11
- 3 fees due Sep 24 to 29, 2027 · next Sep 24
- 11 fees due Oct 14 to 30, 2027 · next Oct 14
- 4 fees due Nov 7 to 14, 2027 · next Nov 7
Recent changes
- Oct 29Assignment recorded on 2 records: Suresh, Kirthana Sreerangathama to Emory University Recorded Oct 29, 2026, executed Jun 6, 2026. Conveyance as recorded: Assignment of Assignor's Interest. A recorded assignment is a filed document, not a statement of current ownership. Reel 76563, frame 634.
- Oct 29Assignment recorded on 5 records: Suresh, Kirthana Sreerangathama to Emory University Recorded Oct 29, 2026, executed Jun 6, 2026. Conveyance as recorded: Assignment of Assignor's Interest. A recorded assignment is a filed document, not a statement of current ownership. Reel 76563, frame 672.
- 13 of the patents on this record were granted since Aug 17, 2026
- 9 terms have ended since Aug 17, 2026
What they patent
The 5 largest of its 344 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Compounds and Compositions for Ossification and Methods Related Thereto | 6 in force | to Jun 2033 |
| Progesterone Phosphate Analogs and Uses Related Thereto | 5 in force | to Aug 2034 |
| Antiviral Jak Inhibitors Useful in Treating or Preventing Retroviral and Other Viral Infections | 5 in force | to May 2033 |
| Lipid Disulfide Prodrugs and Uses Related Thereto | 4 in force | to Jul 2038 |
| Botanical Extracts and Compounds from Schinus Plants and Methods of Use | 4 in force | to Apr 2038 |
Patents held now
Soonest term end first.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,045,727 | Virus-like particles, methods of preparation, and immunogenic compositions In force · High confidence | In force | High confidence | |
| US 7,652,033 | HIF-1 Inhibitors In force · High confidence | In force | High confidence | |
| US 7,686,781 | Catheter for Modified Perfusion In force · High confidence | In force | High confidence | |
| US 10,905,586 | Methods and Devices for Drug Delivery to Ocular Tissue Using Microneedle In force · Medium confidence | In force | Medium confidence | |
| US D685,387 | Graphical User Interface for a Display Screen or a Portion Thereof In force · High confidence | In force | High confidence | |
| US 7,550,299 | Method for Predicting Onset/Risk of Atrial Fibrillation (AF) held by U.S. Department of Veterans Affairs and Emory University In force · High confidence | In force | High confidence | |
| US 10,787,641 | Therapeutic Use of CD31 Expressing Cells In force · High confidence | In force | High confidence | |
| US 7,824,672 | Method for Coating Living Cells In force · High confidence | In force | High confidence | |
| US 7,691,289 | Compositions, Materials Incorporating the Compositions, and Methods of Using the Compositions and Materials In force · High confidence | In force | High confidence | |
| US D696,094 | Accessory Clamp In force · High confidence | In force | High confidence |
Also on record, not counted in the 467: 90 patents in force now held by others · 176 patents ended · 288 applications pending · 433 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.